PARIS, France, April 25, 2022 at 10:15 p.m. (CET) – Pharnext SA (FR0011191287 – ALPHA) (the “Company”), an advanced clinical-stage biopharmaceutical company developing new therapies for neurodegenerative diseases that currently have no satisfactory therapeutic solution, has issued a tenth installment of 300 bonds convertible into shares (the “OCA”) with a nominal value of €10,000 each, within the framework of the contract for the issue of convertible bond issue warrants or exchangeable into new and/or existing shares (the “OCEANE-BSA”) concluded with the company Global Tech Opportunities 13 (the “Investor”).
As for the funds received during the drawing of the previous tranches, the funds paid in the context of this financing will mainly be used to finance the performance of the PREMIER trial, a pivotal Phase III clinical study of PXT3003, the Company’s product candidate in Charcot-Marie-Tooth disease type 1A, and the open-label Phase III extension study.
The terms of this financing are described in the press release published on June 7, 2021 and, with regard to the terms amended by agreement between the Investor and the Company, in the press release dated December 22, 2021 as well as in the Company’s 2021 financial results press release, dated today, for the delayed schedule for the drawdown of the remaining tranches. It is reminded that the program of emitted